Dr. Reddy’s Laboratories Ltd ADRRDY

Capital at risk.

Calendar
event
Ex dividend date
30 Jul 2024
event_available
Last Dividend Payment
12 Aug 2024
About Dr. Reddy’s Laboratories Ltd ADR
Ticker
info
RDY
Trading on
info
NYSE
ISIN
info
US2561352038
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
-
Headquarters
info
8-2-337, Road No. 3, Hyderabad, undefined, India, 500034
Employees
info
27,048
Website
info
drreddys.com
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Metrics
BasicAdvanced
Market cap
info
$11.6B
P/E ratio
info
18.18
EPS
info
$0.77
Dividend Yield
info
0.70%
Beta
info
0.48
Forward P/E ratio
info
16.03
EBIDTA
info
$85.6B
Ex dividend date
info
2024-07-30
Price & volume
Market cap
info
$11.6B
Average daily volume
info
2.8M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$8.00
Dividend yield
info
0.70%
Forward dividend per share
info
$0.10
Forward dividend yield
info
0.70%
Payout ratio
info
0.32%
Valuation
P/E ratio
info
18.18
Forward P/E
info
16.03
PEG ratio
info
4.51
Trailing P/E
info
18.18
Price to sales
info
0.04
Price to book
info
3.12
Earnings
EPS
info
$0.77
EPS estimate (current quarter)
info
$16.15
EPS estimate (next quarter)
info
$16.07
EBITDA
info
$85.6B
Revenues (TTM)
info
$311B
Revenues per share (TTM)
info
$62.42
Technicals
Beta
info
0.48
52-week High
info
$16.89
52-week Low
info
$12.26
50-day moving average
info
$13.21
200-day moving average
info
$14.84
Short ratio
info
7.91
Short %
info
2.44%
Management effectiveness
ROE (TTM)
info
18.47%
ROA (TTM)
info
10.32%
Profit margin
info
17.24%
Gross profit margin
info
$185B
Operating margin
info
22.38%
Growth
Quarterly earnings growth (YoY)
info
2.40%
Quarterly revenue growth (YoY)
info
15.90%
Share stats
Outstanding Shares
info
832M
Float
info
596M
Insiders %
info
-
Institutions %
info
14.96%
Analyst Insights & forecasts
info

40% Buy

40% Hold

20% Sell

Based on information from 5 analysts.

Average price target

info
$14.98
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$78.35
$68.45
14.46%
Q1 • 24Beat
$83.46
$78.22
6.70%
Q2 • 24Beat
$0.18
$0.98
81.63%
Q3 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$80.2B
$12.6B
15.66%
Q3 • 24
$83.6B
$14.1B
16.91%
Q4 • 24
4.27%
12.59%
7.97%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$466B
$157B
33.62%
Q3 • 24
$481B
$159B
33.15%
Q4 • 24
3.24%
1.80%
1.40%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$9.32B
$-19.1B
$16.2B
$1.41B
Q3 • 24
$6.62B
$-5.46B
$590M
$-2.2B
Q4 • 24
28.94%
71.38%
96.35%
256.29%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Dr. Reddy’s Laboratories Ltd ADR share?
Collapse

Dr. Reddy’s Laboratories Ltd ADR shares are currently traded for undefined per share.

How many shares does Dr. Reddy’s Laboratories Ltd ADR have?
Collapse

Dr. Reddy’s Laboratories Ltd ADR currently has 832M shares.

Does Dr. Reddy’s Laboratories Ltd ADR pay dividends?
Collapse

Yes, Dr. Reddy’s Laboratories Ltd ADR does pay dividends.

What is Dr. Reddy’s Laboratories Ltd ADR 52 week high?
Collapse

Dr. Reddy’s Laboratories Ltd ADR 52 week high is $16.89.

What is Dr. Reddy’s Laboratories Ltd ADR 52 week low?
Collapse

Dr. Reddy’s Laboratories Ltd ADR 52 week low is $12.26.

What is the 200-day moving average of Dr. Reddy’s Laboratories Ltd ADR?
Collapse

Dr. Reddy’s Laboratories Ltd ADR 200-day moving average is $14.84.

Who is Dr. Reddy’s Laboratories Ltd ADR CEO?
Collapse

The CEO of Dr. Reddy’s Laboratories Ltd ADR is -.

How many employees Dr. Reddy’s Laboratories Ltd ADR has?
Collapse

Dr. Reddy’s Laboratories Ltd ADR has 27,048 employees.

What is the market cap of Dr. Reddy’s Laboratories Ltd ADR?
Collapse

The market cap of Dr. Reddy’s Laboratories Ltd ADR is $11.6B.

What is the P/E of Dr. Reddy’s Laboratories Ltd ADR?
Collapse

The current P/E of Dr. Reddy’s Laboratories Ltd ADR is 18.18.

What is the EPS of Dr. Reddy’s Laboratories Ltd ADR?
Collapse

The EPS of Dr. Reddy’s Laboratories Ltd ADR is $0.77.

What is the PEG Ratio of Dr. Reddy’s Laboratories Ltd ADR?
Collapse

The PEG Ratio of Dr. Reddy’s Laboratories Ltd ADR is 4.51.

What do analysts say about Dr. Reddy’s Laboratories Ltd ADR?
Collapse

According to the analysts Dr. Reddy’s Laboratories Ltd ADR is considered a buy.